Why would anyone pay $100m for the B Cell platform requiring another $200-$300m in development funding?
Enhertu has secured >50% of the Her-2 BC market (and growing) and generated revenue of US$2.3B last year. As Mason pointed out 3 years ago; Enhertu is vastly superior to anything IMU has (and why their programs continue to be shelved).
$300-$400m to develop a vastly inferior treatment to SOC? Why?
LC and YF might be excited about 'incredible results' - doesn't mean they're commercially viable.
IMU Price at posting:
4.6¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)